bhiva autumn conference

FINAL PROGRAMMEBHIVA Autumn Conference13–14 October 2016QEII CentreLondon

including

CHIVA Parallel SessionsFriday 14 October 2016

18 CPD Credits

Reference No

106110 www.bhiva.org

Preceded bySeventh BHIVA Conference for the Management of HIV/Hepatitis Co-infectionin collaboration with the British Viral Hepatitis Group (BVHG)

Wednesday 12 October 2016

Joining forces, changing futuresHIV in women: science, stigma and society

ViiV Healthcare Symposium: Autumn BHIVA Conference, 2016Thursday 13th October, 09:00–10:00Fleming Hall, Queen Elizabeth II Conference Centre, London

Chaired by Dr Annemiek de Ruiter Honorary consultant in HIV medicine at Guy’s and St Thomas’ NHS Foundation Trust Senior Global Medical Director, ViiV Healthcare

Symposium speakers:Dr Sara Paparini Research Fellow, London School of Hygiene and Tropical Medicine

Paula Evenden Co-Director, Dragonfly Collective

Dr Paul Benn Honorary consultant in HIV medicine at Mortimer Market European Medical Team, ViiV Healthcare

Please join us at 09:00 on Thursday 13th October in the Fleming Hall where our panel will be discussing the inequalities faced by women living with HIV, from socio-cultural aspects, including domestic abuse and stigma through to the imbalance seen with female representation in clinical trials.

Tivicay® dolutegravir 50mg tablets Prescribing InformationSee Summary of Product Characteristics before prescribingIndication: HIV in >12 years and ≥40kg as part of combination therapy. Dosing: 50mg once daily with or without food if no proven/ suspected integrase resistance. 50mg twice daily with efavirenz, nevirapine, tipranavir/ritonavir, etravirine (without boosted PI), carbamazepine, oxcarbazepine, phenytoin, phenobarbital, St John’s Wort or rifampicin. Adults with proven/ suspected integrase resistance: 50mg twice daily preferably with food. Elderly: Limited data in 65+ yrs. Caution in severe hepatic impairment. Contraindications: Hypersensitivity to any ingredient. Co-administration with dofetilide. Warnings/precautions: Risk of hypersensitivity reactions. Discontinue dolutegravir and other suspect agents immediately if suspected. Risks of osteonecrosis, immune reactivation syndrome. Monitor LFTs in Hepatitis B/C co-infection and ensure effective Hepatitis B therapy. Caution with metformin: monitor renal function and consider metformin dose adjustment. Use with etravirine requires boosted PI or increased dose of dolutegravir. Use with Mg/Al-containing antacids, calcium, multivitamins or iron requires dosage separation. Pregnancy/ lactation: Not recommended. Avoid breast- feeding. Side effects: See SPC for full details. Headache,

GI disturbance, insomnia, abnormal dreams, depression, dizziness, rash, pruritus, fatigue, elevations of ALT, AST and CPK, hypersensitivity, suicidal ideation or suicide attempt. Basic NHS costs: 30 tablets £498.75 EU/1/13/892/001. MA holder: ViiV Healthcare UK Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS. Further information available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT.

Tivicay is a registered trademark of the ViiV Healthcare Group of CompaniesDate of approval: August 2015 Zinc code: UK/DLG/0055/13(7)

Adverse events should be reported. For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

Adverse events should be reported. For Ireland, adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971, [email protected]. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

POM

TRIUMEQ and TIVICAY are trademarks of the ViiV Healthcare group of companies. ©ViiV Healthcare group of companies 2015. All rights reserved.

UK/DTGP/0032/16c Date of preparation: September 2016

dolutegravir/abacavir/lamivudine

Prescribing Information

Triumeq® dolutegravir 50mg/abacavir 600mg/ lamivudine 300mg tabletsSee Summary of Product Characteristics before prescribing. Indication: HIV in over 12 years and ≥ 40kg. Screen for HLA-B*5701 prior to use. Do not use if HLA-B*5701 positive. Dose: one tablet once daily with or without food. Elderly: Limited data in 65+ yrs. Creatinine clearance <50ml/min or moderate/severe hepatic impairment: Not recommended. Contraindications: Hypersensitivity to any ingredient. Co-administration with dofetilide. Warnings/precautions: Both abacavir and dolutegravir are associated with risk of hypersensitivity reactions (HSR). Do not initiate in HLA-B*5701+ or previous suspected abacavir HSR. Stop Triumeq without delay if HSR suspected. Never reintroduce any dolutegravir- or abacavir-containing product after suspected HSR. Risks of immune reactivation syndrome, osteonecrosis, increased weight, lipids, glucose. Monitor LFTs in Hepatitis B/C co-infection. Inconclusive data on relationship between abacavir and MI; minimise all modifiable CV risk factors (e.g. smoking, hypertension, hyperlipidaemia). Not recommended if dolutegravir required b.d. (with etravirine [without boosted PI], efavirenz, nevirapine, rifampicin, boosted tipranavir, carbamazepine, oxcarbazepine, phenytoin, phenobarbital and St John’s Wort). Use with cladribine not recommended. Use with Mg/Al-containing antacids, calcium, multivitamins

or iron requires dosage separation. Caution with metformin: monitor renal function and consider metformin dose adjustment. Pregnancy/lactation: Not recommended. Avoid breast-feeding. Side effects: See SPC for details. Headache, insomnia, sleep/dream disorders, GI disturbance, fatigue, hypersensitivity, anorexia, depression, dizziness, somnolence, lethargy, malaise, cough, nasal symptoms, rash, pruritus, alopecia, arthralgia, muscle disorders, asthenia, fever, elevations of ALT, AST and CPK, blood dyscrasias, suicidal ideation or suicide attempt, rhabdomyolysis, lactic acidosis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis. Basic NHS costs: 30 tablets: £798.16 EU/1/14/940/001. MA holder: ViiV Healthcare UK Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS. Further information is available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT.

Triumeq is a registered trademark of the ViiV Healthcare Group of CompaniesDate of approval: July 2016 Zinc code: UK/TRIM/0037/14(5)

POM

10905 ViiV Symposium Programme Advert.indd 1 02/09/2016 14:40

Final Programme 3

London 2016 QEII Centre

Dear Colleague

Welcome to the BHIVA Autumn Conference preceded by the Seventh BHIVA Conference for the Management of HIV/Hepatitis Co-infection. Again, both conferences are held at a

prestigious conference centre in the heart of London.

I would like to thank Chloe Orkin (Chair of the Conferences Subcommittee), Sanjay Bhagani (Chair of the BHIVA Hepatitis Society), Caroline Sabin (Conference Local Host) and all the members of the Conferences Subcommittee for their efforts in preparing an excellent programme for this conference. In addition, we are delighted to once again, hold parallel sessions on Friday in collaboration with the Children’s HIV Association (CHIVA).

The conference sessions will cover a wide range of important topics relevant to HIV. Please refer to the programme pages for a full schedule of topics and timings.

The BHIVA Annual General Meeting will be held on Friday 14 October prior to lunch. I would encourage all BHIVA members to attend this meeting as it provides a forum to present any points they may have to the BHIVA Officers and members of the Executive Committee.

Finally, we would like to thank our sponsors for their continued support of the Association, which assists greatly with covering some of the costs incurred in organising this conference.

We very much hope you enjoy the programme and find it relevant to both your educational and practical needs.

Dr David Asboe Chair, British HIV Association

INTRODUCTION

C O N T E N T S

BHIVA Committees 4

Programme Summary 5

Programme (Hepatitis Co-infection) 6–7

Programme (BHIVA Autumn) 8–11

Programme (CHIVA Parallel) 12–13

Satellite Symposia and Sponsors’ Workshops 14

Conference Information 17–18

Exhibition 19

Speaker Biographies 20–26

Forthcoming Events and Major Sponsors 2016 27

18 CPD Credits Unique reference number 106110

C O N F E R E N C E V E N U E

BHIVA HIV/Hepatitis Conference QEII Centre, Broad Sanctuary, London SW1P 3EE

Registration Sanctuary Foyer, Ground Floor

Lecture Theatre Churchill, Ground Floor

Exhibition and Catering Pickwick, First Floor

Speakers’ Presentation Preview Room Control Room, First Floor

BHIVA Autumn Conference QEII Centre, Broad Sanctuary, London SW1P 3EE


Lecture Theatre (all BHIVA sessions) Fleming, Third Floor

Lunchtime Workshops Abbey, Rutherford, Fourth Floor

Satellite Symposia Fleming, Third Floor

Exhibition, Lunch and Refreshments Britten, Third Floor

Speakers’ Presentation Preview Room East Room, Third Floor

Drinks Reception Britten, Third Floor

CHIVA Parallel Sessions QEII Centre, Broad Sanctuary, London SW1P 3EE


Lecture Theatre Abbey, Fourth Floor

Final ProgrammeBritish HIV Association (BHIVA)

12–14 October 20164


BHIVA COMMITTEES

Dr C Orkin Chair and BHIVA Executive Committee member

Dr L Waters Vice Chair and BHIVA Executive Committee member

Prof C Sabin BHIVA Local Host and Education and Scientific Subcommittee Chair

Dr D Asboe BHIVA Executive Committee member

Prof M Bower BHIVA Executive Committee member

Mr G Brough Invited Representative

Dr D Churchill BHIVA Executive Committee member

Dr M Chaponda BHIVA Executive Committee member

Mr P Clift BHIVA Executive Committee member and Community Representative

Prof B Gazzard CBE BHIVA Executive Committee member

Prof C Leen BHIVA Executive Committee member

Mrs S Morris Invited Representative

Dr A Palfreeman BHIVA Executive Committee member

Dr I Reeves BHIVA Executive Committee member

Dr G Schembri BHIVA Executive Committee member

Dr M Tenant-Flowers Invited Representative

Dr E Wilkins Invited Representative

Chair

Dr S Bhagani Royal Free London NHS Foundation Trust

Vice Chair

Prof M Nelson Chelsea and Westminster Hospital, London

MEMBERS

Dr K Agarwal King’s College Hospital NHS Trust, London

Dr D Asboe Chelsea and Westminster Hospital, London

Dr A Brown Imperial College Healthcare NHS Trust, London

Dr D Chadwick James Cook University Hospital, Middlesbrough

Dr G Cooke Imperial College London

Prof G Foster Queen Mary University of London

Dr A Freedman Cardiff University School of Medicine

Dr R Kulasegaram St Thomas’ Hospital, London

Prof C Leen Western General Hospital, Edinburgh

Dr C Orkin Barts Health NHS Trust, London

Dr E Thomson University of Glasgow

Dr A Ustianowski Chair of BVHG, North Manchester General Hospital

Dr E Wilkins North Manchester General Hospital

UK-CAB representative

Mr R James Birchgrove

CONFERENCES SUBCOMMITTEE

BHIVA HEPATITIS SOCIETY EXECUTIVE PANEL

OFFICERS

Chair

Dr D Asboe Chelsea and Westminster Hospital, London

Vice Chair

Dr A Palfreeman Leicester Royal Infirmary

Honorary Treasurer

Dr D Churchill Royal Sussex County Hospital, Brighton

MEMBERS

Prof B Angus University of Oxford

Prof M Bower Chelsea and Westminster Hospital, London

Dr D Chadwick James Cook University Hospital, Middlesbrough

Dr M Chaponda Royal Liverpool University Hospital

Mr P Clift UK-CAB Community Representative

Prof L Dorrell University of Oxford

Dr A Freedman Cardiff University School of Medicine

Prof B Gazzard CBE Chelsea and Westminster Hospital, London

Dr Y Gilleece Royal Sussex County Hospital, Brighton

Prof C Leen Western General Hospital, Edinburgh

Dr C Orkin Barts Health NHS Trust, London

Dr I Reeves Homerton University Hospital, London

Prof C Sabin University College London

Dr G Schembri Manchester Centre for Sexual Health

Dr A Sullivan Chelsea and Westminster Hospital, London

Dr L Waters Mortimer Market Centre, London

EXECUTIVE COMMITTEE

Final Programme 5


W E D N E S D A Y 1 2 O C T O B E R 2 0 1 6 Seventh BHIVA Conference for the Management of HIV/Hepatitis Co-infection

in collaboration with BVHG

0830–1830 Registration and Exhibition open0855–0900 Welcome Address0900–1100 Session 11100–1130 Morning coffee1130–1230 Gilead Sciences Satellite Symposium1230–1330 Session 21330–1430 Lunch1430–1610 Session 31610–1630 Afternoon tea1630–1730 Plenary Session 41730–1800 Keynote Lecture1800 Close

T H U R S D A Y 1 3 O C T O B E R 2 0 1 6 BHIVA Autumn Conference

0830–1830 Registration and exhibition open0855–0900 Welcome Address0900–1000 ViiV Healthcare UK Satellite Symposium1000–1030 BHIVA Foundation Lecture1030–1100 Morning coffee1100–1200 BHIVA Guidelines Session1200–1230 BHIVA Audit Session1230–1400 Lunch1240–1325 BHIVA Lunchtime Workshop1255–1355 Janssen Lunchtime Workshop1400–1500 BHIVA Plenary Session 11500–1600 BHIVA Plenary Session 21600–1630 Afternoon tea1630–1730 BHIVA Plenary Session 31730–1830 Pfizer Ltd Satellite Symposium1830–1930 Drinks Reception

F R I D A Y 1 4 O C T O B E R 2 0 1 6 BHIVA Autumn Conference CHIVA Parallel Sessions

0815–1440 Registration and exhibition open0900–1000 Gilead Sciences Satellite Symposium Parallel Session 11000–1030 Gazzard Lectureship in HIV Medicine1030–1040 BHIVA Awards Ceremony1040–1110 Morning coffee1110–1140 CHIVA Plenary Lecture Parallel Session 21140–1310 BHIVA Best Practice Management Session1310–1340 BHIVA Annual General Meeting1310–1440 Lunch1345–1430 BHIVA Lunchtime Workshop1440–1540 BHIVA Community Symposium Parallel Session 31540–1640 BHIVA Clinical Conundrums1640–1645 Close

PROGRAMME SUMMARY


12–14 October 20166


PROGRAMME

W E D N E S D A Y 1 2 O C T O B E R 2 0 1 6

√ All sessions to be held in the Churchill, Ground Floor, QEII Centre unless otherwise stated ®

0830–1830 Registration and exhibition open

0855–0900 Welcome and Introduction Churchill, Ground Floor

Dr Sanjay Bhagani Royal Free London NHS Foundation Trust

Dr Andrew Ustianowski North Manchester General Hospital

0900–1100 Session 1: Advances in viral hepatitis management: Bench to clinic

Chairs: Dr Ashley Brown Imperial College Healthcare NHS Trust, London

Dr Chloe Orkin Barts Health NHS Trust, London

Upcoming HCV therapy and ‘difficult-to-treat patients’ Professor Graham Foster Queen Mary University of London

Resistance testing in HCV infection – is it necessary? Professor Jean-Michel Pawlotsky Hôpital Henri-Mondor, Paris, France

New paradigms in HBV management Professor Geoff Dusheiko Royal Free London NHS Foundation Trust

Panel discussion

1100–1130 Morning coffee

1130–1230 Gilead Sciences Satellite Symposium (See page 14 for further information)

1230–1330 Session 2: HIV/Hepatitis co-infection clinical case presentations Facilitators: Dr Ranjababu Kulasegaram

Guy's and St Thomas' NHS Foundation Trust, London

Dr Emma Thomson University of Glasgow

Case report: a treatment dilemma Dr Chris Dugan Royal Free London NHS Foundation Trust

Fallen at the first hurdle Dr Sarah Ramsay Barts Health NHS Trust, London

A wild goose chase Dr Diarmuid Nugent Mortimer Market Centre, London

1330–1430 Lunch

1430–1610 Session 3: UK CHIC Viral Hepatitis Programme

Chairs: Dr Sanjay Bhagani Royal Free London NHS Foundation Trust


Seventh BHIVA Conference for the Management of HIV/Hepatitis Co-infectionin collaboration with the British Viral Hepatitis Group (BVHG)

Final Programme 7


PROGRAMME BHIVA AUTUMN CONFERENCE 2016

W E D N E S D A Y 1 2 O C T O B E R 2 0 1 6

Introduction Professor Caroline Sabin University College London

Summary of ongoing/completed UK CHIC work

Update on the epidemiology of HBV/HCV in the UK CHIC cohort Ms Alicia Thornton University College London

Treatment uptake and outcomes for HCV Dr Richard Gilson University College London

ESLD: referral for transplantation and outcomes Dr Charlotte Warren-Gash University College London

Looking forwards: how can we benefit with wider collaborations?

HCV research/stop HCV Professor William Irving

University of Nottingham

Modelling work Professor Peter Vickerman University of Bristol

Collaborations with PHE Dr Ruth Simmons Public Health England

Panel discussion

1610–1630 Afternoon tea

1630–1730 Session 4: Non-viral Liver Disease

Chairs: Dr Graham Cooke Imperial College London

Dr Yvonne Gilleece Royal Sussex County Hospital, Brighton

Non-alcoholic fatty liver: a practical approach Professor Mark Thursz University College London

How important is alcohol as a contributor to liver disease in patients with viral hepatitis and HIV? Dr Vincent Mallet Université Paris Descartes, France

1730–1800 Keynote Lecture: Global Issues in HCV

Elimination of HCV: a reality? Dr Gail Matthews University of New South Wales, Australia

Gilead Sciences have made a contribution towards the funding of this lecture. Gilead Sciences have had

no involvement with the selection of the speaker or content of this lecture.

1800 Case presentation prize and close by the Chair of the British Viral Hepatitis Group



12–14 October 20168



T H U R S D A Y 1 3 O C T O B E R 2 0 1 6√ All sessions to be held in the Fleming, Third Floor, QEII Centre unless otherwise stated ®


0855–0900 Welcome Address by the Chair of the British HIV Association

Dr David Asboe Chelsea and Westminster Hospital, London

0900–1000 ViiV Healthcare UK Satellite Symposium (See page 14 for further information)

1000–1030 BHIVA Foundation Lecture

Chair: Dr David Asboe Chelsea and Westminster Hospital, London

Visceral adiposity in the modern era

Dr Jordan Lake The University of Texas Health Science Centre at Houston, USA


1100–1200 BHIVA Guidelines Session

Chairs: Dr Duncan Churchill Royal Sussex County Hospital, Brighton

Dr Adrian Palfreeman Leicester Royal Infirmary

Guidelines on the use of pre-exposure prophylaxis

Dr Michael Brady King’s College Hospital, London

Dr Alison Rodger University College London

Guidelines for the treatment of TB/HIV co-infection

Dr Frank Post King’s College Hospital, London

Guidelines for the management of sexual and reproductive health of people living with HIV infection

Dr Laura Waters Mortimer Market Centre, London

1200–1230 BHIVA Audit Session

Chair: Dr Andrew Freedman Cardiff University School of Medicine

Review of late diagnoses and survey of access to seasonal influenza vaccine Dr Ruth Byrne Chelsea and Westminster Hospital, London

1230–1400 Lunch and Lunchtime Workshops

1240–1325 BHIVA Lunchtime Workshop (Abbey, Fourth Floor) Clinico-pathological case presentations

Facilitators: Dr Ula Mahadeva St Thomas’ Hospital, London

Dr Melinda Tenant-Flowers Retired Consultant in HIV and Sexual Health Medicine

Final Programme 9



T H U R S D A Y 1 3 O C T O B E R 2 0 1 6

A difficult case to get your head around Dr Charles Williams King's College Hospital, London

Dressed to the 16's Dr Emily Chung Mortimer Market Centre, London

TB or not to be Dr Hardeep Kang Blackpool Hospitals NHS Foundation Trust

1255–1355 Janssen Lunchtime Workshop (Rutherford, Fourth Floor) (See page 14 for further information)

1400–1500 BHIVA Plenary Session 1

Chairs: Dr Chloe Orkin Barts Health NHS Trust, London

Dr Ann Sullivan Chelsea and Westminster Hospital, London

HIV, STIs, HCV – how can better commissioning improve outcomes? Professor Simon Barton Chelsea and Westminster Hospital, London

BHIVA Primary Care Project Dr Maryam Shahmanesh

UCL Institute of Epidemiology and Health Care, London


Chairs: Dr Iain Reeves Homerton University Hospital, London

Professor Caroline Sabin University College London

Testing and treatment of HIV within 24 hours: is it viable? Dr Nneka Nwokolo

Chelsea and Westminster Hospital, London

Long-acting treatment with antiretrovirals Professor Saye Khoo

University of Liverpool

1600–1630 Afternoon tea


Chairs: Professor Lucy Dorrell University of Oxford

Dr Gabriel Schembri Manchester Centre for Sexual Health

PrEP: the politics and practicalities of implementation Dr Laura Waters Mortimer Market Centre, London

Engagement and the HIV cascade of care Professor Tim Rhodes London School of Hygiene and Tropical Medicine

1730–1830 Pfizer Satellite Symposium (See page 14 for further information)

1830–1930 Drinks Reception


12–14 October 201610


F R I D A Y 1 4 O C T O B E R 2 0 1 6√ All sessions to be held in the Fleming, Third Floor, QEII Centre unless otherwise stated ®


0900–1000 Gilead Sciences Satellite Symposium (See page 14 for further information)

1000–1030 Gazzard Lectureship in HIV Medicine

Chair: Dr David Asboe Chelsea and Westminster Hospital, London

HIV remission: viral suppression in the absence of ART Professor Sarah Fidler Imperial College Healthcare NHS Trust, London

1030–1040 BHIVA Awards Ceremony


1110–1140 CHIVA Plenary Lecture

Chair: Dr Amanda Williams London North West Healthcare NHS Trust

HIV gene therapy Professor Waseem Qasim Great Ormond Street Hospital, London

1140–1310 BHIVA Best Practice Management Session

Chairs: Professor Brian Angus University of Oxford

Dr Adrian Palfreeman Leicester Royal Infirmary

Investigating general liver disease/transaminitis Dr Emmanuel Tsochatzis University College London

Managing cryptococcal meningitis Professor Tom Harrison St George’s Healthcare NHS Trust, London

Frailty Dr John Soong Imperial College Healthcare NHS Trust, London

1310–1340 BHIVA Annual General Meeting (members only)


1345–1430 BHIVA Lunchtime Workshop (Abbey, Fourth Floor) Pregnancy and breastfeeding case presentations

Facilitators: Dr Yvonne Gilleece Royal Sussex County Hospital, Brighton

Dr Liat Sarner Barts Health NHS Trust, London

Challenges of breastfeeding, where to draw the line Dr Seema Malik Royal Bournemouth Hospital

Pregnancy in HIV-2 infection Dr Kanch Seneviratne Nottingham University Hospitals


Final Programme 11


F R I D A Y 1 4 O C T O B E R 2 0 1 6

Primary or reactivation? Dr Martin Lechelt Orsett Hospital, Grays, Essex

1440–1540 BHIVA Community Symposium

Chairs: Dr David Chadwick James Cook University Hospital, Middlesbrough

Mr Paul Clift King's College Hospital NHS Foundation Trust

What are the effects of ‘austerity’ on the HIV population?

Local perspective: two cases of PLWHIV who have been affected by ‘austerity’ Ms Marie Rousseau King’s College Hospital, London

National perspective: the current health of UK-based HIV/AIDS organisations and the effects of ‘austerity’ Mr Andrew Dalton University of Sunderland

International commitments: ‘austerity’ and ending AIDS by 2030 Mr Bryan Teixeira European AIDS Treatment Group (EATG)

1540–1640 BHIVA Clinical Conundrums

Chair: Dr Mas Chaponda Royal Liverpool University Hospital

Panellists: Professor Mark Bower Chelsea and Westminster Hospital, London

Professor Clifford Leen Western General Hospital, Edinburgh

Dr Melinda Tenant-Flowers Retired Consultant in HIV and Sexual Health Medicine

First-line treatment failure Dr Nicola Mackie Imperial College Healthcare NHS Trust, London

Management of diabetes Professor Karim Meeran Imperial College Healthcare NHS Trust, London

Opportunistic infections Dr Ed Wilkins North Manchester General Hospital

1640–1645 Case presentation prizes and close by the new Chair of the British HIV Association Dr Chloe Orkin

Barts Health NHS Trust, London



12–14 October 201612


PROGRAMME CHIVA PARALLEL SESSIONS 2016

F R I D A Y 1 4 O C T O B E R 2 0 1 6

Please read the CHIVA Parallel Sessions programme in conjunction with the BHIVA Autumn Conference programme

√ All sessions to be held in the Abbey, Fourth Floor, QEII Centre unless otherwise stated ®


0855–0900 Welcome Address by the Chair of the Children’s HIV Association Dr Amanda Williams London North West Healthcare NHS Trust

0900–1040 CHIVA Parallel Session 1

Chairs: Dr Tomás Campbell Consultant Clinical Psychologists in Private Practice

Dr Fiona Shackley Sheffield Children's Hospital

0900–0940 Achieving well-being for young people: young people’s experiences and clinical responses; remaining engaged with young people who disengage

Ms Amanda Ely Children's HIV Association

Dr Caroline Foster Imperial College Healthcare NHS Trust, London

0940–1010 Showing of a CHIVA young people’s film

1010–1040 Psychological coping strategies: child and adolescent mental health

Dr Jackie Nicholson Clinical Psychologist, Manchester


1110–1140 CHIVA Plenary Lecture Fleming, Third floor (See page 10 for further details) HIV gene therapy Professor Waseem Qasim Great Ormond Street Hospital, London


Chairs: Dr Jolanta Bernatoniene Bristol Royal Hospital for Children

Dr Katja Doerholt St George's Hospital, London

1150–1210 CHIVA Projects update

1210–1230 CHIVA Youth Committee session

1230–1310 Developments around PrEP

Dr Steve Taylor Birmingham Heartlands Hospital

1310–1340 BHIVA Annual General Meeting (members only)


Children’s HIV Association (CHIVA) Parallel Sessions

Final Programme 13


PROGRAMME CHIVA PARALLEL SESSIONS 2016

F R I D A Y 1 4 O C T O B E R 2 0 1 6


Chairs: Dr Alasdair Bamford Great Ormond Street Hospital, London

Dr Anna Turkova Imperial College Healthcare NHS Trust, London

1440–1505 New antiretroviral drugs on the horizon

Mrs Kate Gandhi Birmingham Heartlands Hospital

1505–1530 Talking about HIV to a young person with learning difficulties

Mrs Yvonne Vaughan-Gordon Birmingham Heartlands Hospital

1530–1555 AALPHI update

Dr Ali Judd MRC Clinical Trials Unit at UCL, London

1555–1625 HIV cure research agenda

Professor Nigel Klein University College London

1625–1655 Stigma and sexual health: Developing coping strategies; when to worry and when to refer

Ms Claire McCausland University of Central Lancashire

1655 Close by the Chair of the Children’s HIV Association

Dr Amanda Williams London North West Healthcare NHS Trust


12–14 October 201614


PROGRAMME OF SATELLITE SYMPOSIA AND SPONSORS’ LUNCHTIME WORKSHOPS

W E D N E S D A Y 1 2 O C T O B E R1130–1230 Gilead Sciences Satellite Symposium (Churchill, Ground Floor)

Simple HCV therapy – transforming the epidemic Chair: Dr Andrew Ustianowski

North Manchester General Hospital

The journey to pan-genotypic HCV therapy options Dr Mas Chaponda Royal Liverpool University Hospital

Impacting the prevalence – the way forward Dr Laura Waters Mortimer Market Centre, London

Panel discussion

T H U R S D A Y 1 3 O C T O B E R0900–1000 ViiV Healthcare UK Satellite Symposium (Fleming, Third Floor)

HIV in women: science, stigma and society Chair: Dr Annemiek de Ruiter

ViiV Healthcare UK and Guy’s and St Thomas’ NHS Foundation Trust, London

Speakers Dr Paul Benn ViiV Healthcare UK and Mortimer Market Centre, London

Dr Sara Paparini London School of Hygiene and Tropical Medicine

Mrs Paula Evenden Dragonfly Collective

1255–1355 Janssen Lunchtime Workshop (Rutherford, Fourth Floor) Tailoring care: how and when to use different ARVs to address diverse patient needs Chair: Dr Anton Pozniak

Chelsea and Westminster Hospital, London

Speaker Dr Marta Boffito Chelsea and Westminster Hospital, London

1730-1830 Pfizer Satellite Symposium (Fleming, Third Floor) The journey of accessing pneumococcal vaccinations – the path, the hurdles and the potential solutions Chair: Professor Anna Maria Geretti

University of Liverpool

Co-chair: Dr George Kassianos British Global & Travel Health Association and Ringmead Medical Practice

Dr David Chadwick James Cook University Hospital, Middlesbrough

Dr Catherine Heffernan NHS England (London Region) and London School of Hygiene and Tropical Medicine

F R I D A Y 1 4 O C T O B E R0900–1000 Gilead Sciences Satellite Symposium (Fleming, Third Floor)

Achieving a balance: planning ahead for the real world challenges we face in HIV Chair: Dr Iain Reeves

Homerton University Hospital, London

Speakers Dr Christoph Spinner Technical University of Munich, Germany

Dr Paddy Mallon Mater Misericordiae University Hospital, Dublin, Ireland

DESCOVY® BASED INTEGRASE INHIBITOR STR2

DESCOVY® BASED STR WITH A BHIVA PREFERRED NNRTI3,4

INTRODUCING DESCOVY® A TAF BASED BACKBONE1

Odefsey® is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus-1 (HIV-1) without known mutations associated with resistance to the NNRTI class, tenofovir or emtricitabine and with a viral load ≤100,000 HIV-1 RNA copies/mL3

Descovy® is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type-1 (HIV-1)1

Genvoya® is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus-1 (HIV-1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir2

Prescribing information for Odefsey®, Descovy® and Genvoya® is available overleaf.

Job number: FTAF/UK/16-06/MI/1177(1)Date of preparation: August 2016TAF, tenofovir alafenamide

GSU13J16036_Portfolio 2pp Ad_A4_V1.2_FAW.indd 1 9/26/16 3:04 PM

DESCOVY® PRESCRIBING INFORMATIONConsult the Summary of Product Characteristics (SPC) before prescribing. Descovy®▼ emtricitabine 200mg/ tenofovir alafenamide 10mg or 25mg film coated tablets.Indication: In combination with other antiretroviral agents for the treatment of HIV-1 infection in adults & adolescents (aged 12 years & older weighing at least 35 kg). Dosage: Adults & adolescents (aged ≥ 12 years, weighing at least 35 kg): One tablet, once daily, orally with or without food. The dose of Descovy should be administered according to the third agent in the HIV treatment regimen. Please consult the SPC for further information. Children (< 12 years or weighing < 35kg): Safety & efficacy has not been established. Elderly: No dose adjustment is required. Renal: No dose adjustment is required in adult or adolescent patients (aged ≥ 12 years, weighing at least 35 kg) with estimated creatinine clearance (CrCl) ≥ 30 mL/min. In patients with CrCl < 30 mL/min: not recommended. Should be discontinued in patients whose CrCl declines to < 30 mL/min during treatment. Hepatic: Mild/moderate hepatic impairment: no dose adjustment required. Severe hepatic impairment: not recommended. Contraindications: Hypersensitivity to the active substances or to any excipients. Warnings & Precautions: Safety & efficacy in HBV/HCV co-infection has not been established. Co-infected HIV/HBV patients should be closely monitored for at least several months following discontinuation for symptoms of severe acute exacerbations of hepatitis. Descovy should be avoided in antiretroviral patients with HIV-1 harbouring the K65R mutation. Risks of mitochondrial dysfunction, immune reactivation syndrome, opportunistic infections, osteonecrosis

with CART therapy. Interactions: Co-administration with certain anticonvulsants (eg. carbamazepine, oxcarbazepine, phenobarbital & phenytoin), antimycobacterials (eg. rifampicin, rifabutin & rifapentine), boceprevir, telaprevir, St. John’s wort and HIV PIs other than atazanavir, lopinavir and darunavir is not recommended. Should not be administered concomitantly with medicines containing tenofovir disoproxil (as fumarate), lamivudine or adefovir dipivoxil. Co-administration of emtricitabine with medicinal products that are eliminated by active tubular secretion may increase concentrations of emtricitabine. Medicinal products that decrease renal function may increase concentrations of emtricitabine. Medicinal products that induce P-glycoprotein (P-gp) are expected to decrease the absorption of tenofovir alafenamide, resulting in decreased plasma concentration of tenofovir alafenamide, which may lead to loss of therapeutic effect of Descovy and development of resistance. Co-administration with medicinal products that inhibit P-gp are expected to increase the absorption and plasma concentration of tenofovir alafenamide. Tenofovir alafenamide is a substrate of OATP1B1 and OATP1B3 in vitro. The distribution of tenofovir alafenamide in the body may be affected by the activity of OATP1B1 and OATP1B3. Pregnancy & lactation: Use in pregnancy only if potential benefit justifies the potential risk to the foetus. Breast-feeding; not recommended. Side effects: Refer to SPC for full information regarding side effects. Very common (≥1/10): Nausea. Common (≥1/100 to <1/10): Headache, dizziness, diarrhoea, vomiting, abdominal pain, flatulence, abnormal dreams, rash & fatigue. Uncommon (≥1/1000 to <1/100): anaemia, arthralgia, dyspepsia,

angioedema & pruritus. Legal Category: POM. Pack: Bottle of 30 film-coated tablets. Price: UK NHS List Price – £355.73; Eire/Ireland – €587.98. Marketing Authorisation Number: EU/1/16/1099/001; EU/1/16/1099/003.Further information is available from Gilead Sciences Ltd, 280 High Holborn, London, WC1V 7EE, UK; Telephone: +44 (0) 8000 113700, For Ireland: +353 214 825 999. E-mail: [email protected]. Descovy is a trademark. Date of approval: June 2016; FTAF/UK/16-03/MM/1052(1).

▼ This medicinal product is currently subject to additional monitoring. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse reactions to Descovy should be reported to Gilead via email to [email protected] or by telephone +44 (0) 1223 897500.

Adverse events should be reported. For the UK, reporting forms and information can be found at

www.yellowcard.mhra.gov.uk

For Ireland, suspected adverse reactions should be reported to the HPRA Pharmacovigilance using a Yellow Card obtained either from the HPRA, or electronically via the website at www.hpra.ie. Adverse reactions can

also be reported to the HPRA by calling +353 1 6764971.

GENVOYA® PRESCRIBING INFORMATIONConsult the Summary of Product Characteristics before prescribing. GENVOYA®▼ elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/ tenofovir alafenamide 10mg film coated tablets. Indication: Treatment of HIV-1 infection in adults & adolescents (aged 12 years & older weighing at least 35 kg) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir. Dosage: Adults & adolescents (aged ≥ 12 years, weighing at least 35 kg): One tablet, once daily, orally & whole with food. Children (< 12 years or weighing < 35kg): Safety & efficacy has not been established. Elderly: No dose adjustment is required. Renal: No dose adjustment is required in adult or adolescent patients (aged ≥ 12 years, weighing at least 35 kg) with estimated creatinine clearance (CrCl) ≥ 30 mL/min. In patients with CrCl < 30 mL/min: not recommended. Should be discontinued in patients whose CrCl declines to < 30 mL/min during treatment. Hepatic: Mild/moderate hepatic impairment: no dose adjustment required. Severe hepatic impairment: not recommended. Contraindications: Hypersensitivity to the active substances or to any excipients. Coadministration with alfuzosin, amiodarone, quinidine, carbamazepine, phenobarbital, phenytoin, rifampicin, dihydroergotamine, ergometrine, ergotamine, cisapride, St. John’s wort, lovastatin, simvastatin, pimozide, sildenafil for treatment of pulmonary arterial hypertension & oral midazolam & triazolam. Warnings & Precautions: Should not be co-administered with other antiretroviral products. Safety & efficacy in HBV/HCV co-infection has not been established. Co-infected HIV/HBV patients should be closely monitored for at least several months following discontinuation for symptoms of severe acute exacerbations of hepatitis. Should not be administered

concomitantly with medicines containing tenofovir disoproxil (as fumarate), lamivudine or adefovir for treatment of HBV infection. Patients with galactose intolerance, Lapp lactase deficiency & glucose-galactose malabsorption should not take Genvoya. Women of childbearing potential should use either a hormonal contraceptive containing at least 30 µg ethinylestradiol & norgestimate as the progestagen or an alternative reliable method of contraception. Risks of mitochondrial dysfunction, immune reactivation syndrome, opportunistic infections, osteonecrosis with nucleoside analogues & CART therapy. Interactions: Co-administration with medicines that induce/inhibit CYP3A may affect the exposure of elvitegravir by decreasing its plasma concentrations leading to a reduced therapeutic effect of Genvoya. Cobicistat is an inhibitor of CYP3A & is a CYP3A substrate. Medicines highly dependent on CYP3A metabolism & have high first pass metabolism are most susceptible to large increases in exposure when co-administered with cobicistat. Medicines that inhibit CYP3A may decrease the clearance of cobicistat, resulting in increased plasma concentrations of cobicistat. Co-administration with medicines that are substrates of P-gp, BCRP, OATP1B1 & OATP1B3 may result in increased plasma concentrations of these products. Medicines that decrease renal function may increase concentrations of emtricitabine. Pregnancy & lactation: Should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus. It should not be used during breast-feeding. Side effects: Refer to SPC for full information regarding side effects. Very common (≥1/10): Nausea. Common (≥1/100 to <1/10): Headache, dizziness, diarrhoea, vomiting, abdominal pain, flatulence, abnormal dreams, rash & fatigue. Uncommon (≥1/1000 to <1/100): anaemia, depression, dyspepsia,

angioedema & puritus. Legal Category: POM. Pack: Bottle of 30 film-coated tablets. Price: UK NHS List Price - £879.51; Éire/Ireland – €1266.00. Marketing Authorisation Number: EU/1/15/1061/001Further information is available from Gilead Sciences Ltd, 280 High Holborn, London, WC1V 7EE, UK; Telephone: +44 (0) 8000 113700. E-mail: [email protected]. Genvoya is a trademark. Date of approval: July 2016. Job Bag No: TAF/UK/15-09/MM/1098(1).

▼ This medicinal product is currently subject to additional monitoring. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse reactions to Genvoya should be reported to Gilead via email to [email protected] or by telephone +44 (0) 1223 897500.


www.mhra.gov.uk/yellowcard.

For Ireland, suspected adverse reactions should be reported to the HPRA Pharmacovigilance using a Yellow

Card obtained either from the HPRA, or electronically via the website at www.hpra.ie. Adverse reactions can also

be reported to the HPRA by calling +353 1 6764971.

ODEFSEY® PRESCRIBING INFORMATIONConsult the Summary of Product Characteristics (SPC) before prescribing. Odefsey®▼ emtricitabine 200mg/ rilpivirine 25mg/ tenofovir alafenamide 25mg film coated tablets. Indication: Treatment of HIV-1 infection in adults & adolescents (aged 12 years & older weighing at least 35 kg) without any known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor class, tenofovir or emtricitabine and with a viral load ≤ 100,000 HIV-1 RNA copies/mL. Dosage: Adults & adolescents (aged ≥ 12 years, weighing at least 35 kg): One tablet, once daily, orally with food. Children (< 12 years or weighing < 35kg): Safety & efficacy has not been established. Elderly: No dose adjustment is required. Renal: No dose adjustment is required in adult or adolescent patients (aged ≥ 12 years, weighing at least 35 kg) with estimated creatinine clearance (CrCl) ≥ 30 mL/min. In patients with CrCl < 30 mL/min: not recommended. Should be discontinued in patients whose CrCl declines to < 30 mL/min during treatment. Hepatic: Mild/moderate hepatic impairment: no dose adjustment required. Use with caution in patients with moderate hepatic impairment. Severe hepatic impairment: not recommended. Contraindications: Hypersensitivity to the active substances or to any excipients. It should not be co administered with medicines that can result in significant decreases in rilpivirine plasma concentrations (due to cytochrome P450 [CYP]3A enzyme induction or gastric pH increase), which may result in loss of therapeutic effect of Odefsey including: carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampicin, rifapentine, omeprazole, esomeprazole, dexlansoprazole, lansoprazole, pantoprazole, rabeprazole, dexamethasone (oral and parenteral doses), except as a single dose treatment, St. John’s wort. Warnings & Precautions: There are insufficient data to justify the use in patients with prior NNRTI failure. Resistance testing and/or historical resistance data should guide the use of Odefsey. At supratherapeutic doses (75 mg once daily and 300 mg once daily), rilpivirine has been associated with prolongation of the QTc interval of the electrocardiogram (ECG). Should be used with caution when co administered with medicines with a known risk of

Torsade de Pointes. Safety & efficacy in HBV or HCV co-infection has not been established. Co-infected HIV/HBV patients should be closely monitored with both clinical and laboratory follow up for at least several months following discontinuation for symptoms of severe acute exacerbations of hepatitis. The safety and efficacy of Odefsey in patients with significant underlying liver disorders have not been established. Risks of mitochondrial dysfunction, immune reactivation syndrome, opportunistic infections, osteonecrosis with CART therapy. Should not be co-administered with other antiretroviral medicines or with other medicines containing tenofovir alafenamide, lamivudine, tenofovir disoproxil (as fumarate) or adefovir dipivoxil. Interactions: Co-administration of emtricitabine with medicines that are eliminated by active tubular secretion may increase concentrations of emtricitabine and/or the co administered medicines. Medicines that decrease renal function may increase concentrations of emtricitabine. Rilpivirine is primarily metabolised by CYP3A. Medicines that induce or inhibit CYP3A may thus affect the clearance of rilpivirine. Medicines that induce P-glycoprotein (P-gp) are expected to decrease the absorption of tenofovir alafenamide, resulting in decreased plasma concentration of tenofovir alafenamide, which may lead to loss of therapeutic effect of Odefsey and development of resistance. Co-administration with medicines that inhibit P-gp are expected to increase the absorption and plasma concentration of tenofovir alafenamide. Tenofovir alafenamide is a substrate of OATP1B1 and OATP1B3 in vitro. The distribution of tenofovir alafenamide in the body may be affected by the activity of OATP1B1 and OATP1B3. Pregnancy & lactation: Use in pregnancy only if potential benefit justifies the potential risk to the foetus. Breast-feeding; not recommended. Side effects: Refer to SPC for full information regarding side effects. Very common (≥1/10): increased total cholesterol (fasted), increased LDL cholesterol (fasted), insomnia, headache, dizziness, nausea, increased pancreatic amalyse, increased transaminases (AST and/or ALT). Common (≥1/100 to <1/10): decreased white blood cell count, decreased haemoglobin, decreased platelet count, decreased appetite, increased triglycerides (fasted), depression,

abnormal dreams, sleep disorders, depressed mood, somnolence, abdominal pain, vomiting, increased lipase, abdominal discomfort, dry mouth, flatulence, diarrhoea, increased bilirubin, rash, fatigue. Uncommon (≥1/1000 to <1/100): anaemia, immune reactivation syndrome, dyspepsia, severe skin reactions with systemic symptoms, angioedema, pruritus, arthralgia. Legal Category: POM. Pack: Bottle of 30 film-coated tablets. Price: UK NHS List Price – £525.95; Eire/Ireland – TBC. Marketing Authorisation Number: EU/1/16/1112/001; EU/1/16/1112/002.Further information is available from Gilead Sciences Ltd, 280 High Holborn, London, WC1V 7EE, UK; Telephone: +44 (0) 8000 113700, For Ireland: +353 214 825 999. E-mail: [email protected]. Odefsey is a trademark. Date of approval: June 2016; ODE/UK/16-05/MM/1015

▼ This medicinal product is currently subject to additional monitoring. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse reactions to Odefsey should be reported to Gilead via email to [email protected] or by telephone +44 (0) 1223 897500.


www.yellowcard.mhra.gov.uk.

For Ireland, suspected adverse reactions should be reported to the HPRA Pharmacovigilance using a Yellow Card obtained either from the HPRA, or electronically via the website at www.hpra.ie. Adverse reactions can also

be reported to the HPRA by calling +353 1 6764971.

REFERENCES:1. SmPC Descovy®. Available at http://www.medicines.org.uk/emc2. SmPC Genvoya®. Available at http://www.medicines.org.uk/emc3. SmPC Odefsey®. Available at http://www.medicines.org.uk/emc4. British HIV Association guidelines for the treatment of

HIV-1-positive adults with antiretroviral therapy 2015. (2016 interim update). Available at: https://www.bhiva.org/documents/Guidelines/Treatment/2016/treatment-guidelines-2016-interim-update.pdf

ABBREVIATIONS:BHIVA, British HIV Association; NNRTI, non-nucleoside reverse-transcriptase inhibitor; RNA, ribonucleic acid; STR, single-tablet regimen.

GSU13J16036_Portfolio 2pp Ad_A4_V1.2_FAW.indd 2 9/26/16 3:04 PM

Final Programme 17


CONFERENCE INFORMATION

BHIVA Autumn Conference: 13–14 October 2016Your registration fee gives access to the scientific sessions of the BHIVA Autumn Conference and the CHIVA Parallel Sessions, including

satellite symposia. All refreshments and lunches throughout the conference are included in the registration fee.

The Parallel Sessions are preceded by the CHIVA Dinner at Jamie’s Italian, Victoria from 2000 on Thursday 13 October for those who

have booked tickets and paid the necessary fee

BHIVA Lunchtime WorkshopsPlaces are limited and will be restricted to 80 delegates per workshop. Places will be available on site, on a first-come ,first-served basis,

at the door of the lunchtime workshop. Doors will open 15 minutes prior to the start of each workshop.

Each workshop will begin promptly and refreshments will be provided for delegates attending these sessions.

Prizes and awards

The Don Jeffries BHIVA Research Award

BHIVA created this award in honour of the late Professor Don Jeffries. This will be awarded for the highest-scoring application, as

judged by the BHIVA Research Awards Judging Panel, from the 11 applications submitted for the 2016 BHIVA Research Awards. The

award will be presented in the Lecture Theatre at the BHIVA Awards Ceremony at 1030–1040 on Friday 14 October 2016.

BHIVA Best HIV/Hepatitis Co-infection Case Presentation

A prize will be awarded to the presenter of the best case as part of the Difficult HIV/Hepatitis Co-infection Case Presentation Session

to be held at the Seventh BHIVA Conference for the Management of HIV/Hepatitis Co-infection in collaboration with BVHG.

BHIVA Best Clinico-pathological and Best pregnancy and breastfeeding case presentations

A prize will be awarded to the presenter of the best case for each of the above workshops.

Drinks ReceptionThe Drinks Reception immediately follows the conference programme at 1830–1930 on Thursday 13 October and will take place in

the exhibition area located in the Britten on the Third Floor.

Continuing Professional Development (CPD)Medical staff in career grade posts who are enrolled with one of the Royal Medical Colleges for Continuing Professional Development

will receive CPD credit at the rate of one CPD credit per conference hour (exclusive of travel, refreshments, social events and satellite

symposia). The conference will be allocated a maximum of 6 CPD credits per conference day.

BHIVA Community RegistrationBHIVA has supported free registrations for over 50 community representatives to attend the conference.

BHIVA Registration ScholarshipsBHIVA Registration Scholarships have been made available to 10 delegates who are doctors and who are retired, not working or

employed in a part-time or equivalent capacity, or who are students involved in full-time undergraduate or post-graduate work. The

scholarships cover the conference registration fee.

CloakroomA staffed cloakroom is available at the QEII Centre. All belongings are left at the owner’s risk. The QEII Centre and the British HIV

Association do not accept responsibility for the loss of, or damage to, delegates’ personal property stored in the cloakroom areas.

Seventh BHIVA Conference for the Management of HIV/Hepatitis Co-Infection

BHIVA Autumn Conference including CHIVA Parallel Sessions

CHIVA Parallel Sessions only

6 Credits

12 Credits

6 Credits

106110

106110

106110

CPD Accreditation: Credits attributed and unique reference number


12–14 October 201618


Conference venue

QEII Centre Broad Sanctuary · Westminster · London SW1P 3EE · ☎ +44 (0)20 7222 5000 · fl www.qeiicc.co.uk

The conference venue is a short walk from Westminster or St James’s Park underground stations. Please see the map for the location of these stations in relation to the QEII Centre.

Westminster and St James’s Park underground stations are easily accessible from King’s Cross, St Pancras (Eurostar) and Victoria main-line rail stations and can be accessed by the Jubilee line or the Circle and District lines. The journey from these main-line stations to Westminster or St James’s Park underground stations takes approximately 10 minutes.

There are also good links to the city centre from both Heathrow and Gatwick airports. Journeys by either Heathrow or Gatwick Express take about 1 hour.

There are four car parks near to the conference venue. For

further information please visit www.ncp.co.uk

Please note that the conference venue is located within the

London Congestion Charge Zone.

CONFERENCE INFORMATION

QEII Centre

Final Programme 19


Hepatitis Exhibition Floorplan Pickwick, First Floor

Autumn Exhibition Floorplan Britten, Third Floor

Catering Catering

1

2

3

4

Office

FIRE EXIT FIRE EXIT

LiftLiftLift

LiftLiftLift

Lift

Lift

Lift

Ladiesand

GentsWC

Ladiesand

GentsWC

Britten

5 47 6810 9

18

1

2

3

11 1312

17 16 15 14

Catering Catering

Coffee

Cat

erin

g

Cat

erin

g

EXHIBITION FLOOR PLAN AND EXHIBITORS

1 Gilead Sciences Ltd

2 AbbVie Ltd

3 MSD Ltd

4 Bristol-Myers Squibb Pharmaceuticals Ltd

EXHIBITORS

1 Bristol-Myers Squibb Pharmaceuticals Ltd

2 MSD Ltd

3 ViiV Healthcare UK

4 Positively UK

5 Mildmay

6 National AIDS Trust

7 UK-CAB/ HIV i-Base

8 The Sophia Forum

9 NAM

10 Naz Project

11 Janssen

12 ViiV Healthcare UK

13 Positive Conversations

14 Children's HIV Association (CHIVA)

15 Body and Soul

16 Terrence Higgins Trust

17 Saving Lives

18 Gilead Sciences Ltd

EXHIBITORS


12–14 October 201620


PLENARY SPEAKER BIOGRAPHIES

David Asboe is Clinical Director of HIV Medicine and Sexual Health at Chelsea and Westminster Hospital, London. He has been Chair of the British HIV Association since 2013 and is also Convenor of the Diploma in HIV Medicine exam run by the Worshipful Society of Apothecaries.

Simon Barton is a Consultant HIV and GUM Physician at the Chelsea and Westminster Hospital NHS Foundation Trust. He is Associate Medical Director for Integrated Care, previously being Clinical Director HIV, GUM, Pathology and Dermatology for 18 years until 2015. He was the first Chair of the HIV CRG for 3 years and is now Clinical Chair of the Blood and Infection National Programme of Care Board at NHS England.

Sanjay Bhagani is a Consultant Physician in Infectious Diseases and HIV Medicine at the Royal Free Hospital, London and Honorary Senior Lecturer in Infectious Diseases at University College London. He established and is the current lead of a multi-disciplinary HIV/hepatitis co-infection service at the Royal Free and is the current Chair of BHIVA’s Viral Hepatitis Group. He serves on the HIV/hepatitis guidelines subcommittees for both BHIVA and the European AIDS Clinical Society and is also on the editorial boards of AIDS Research and Therapy and BMC Hepatology, Medicine and Policy and is a trustee at AIDSOrphan.

Michael Brady is a Consultant in Sexual Health and HIV at King’s College Hospital, London and the Medical Director for Terrence Higgins Trust. He has a particular interest in HIV testing and prevention of transmission, and has been involved in a number of projects to develop and evaluate novel HIV testing strategies, including community and outreach point-of-care testing, on-line home HIV and STI sampling, and HIV self-testing.

Ruth Byrne is a Specialty Registrar in GU and HIV Medicine. She is a member of the BHIVA Audit subcommittee and worked on the national audit of HIV late diagnoses. She is currently working as a Clinical Research Fellow at the Institute of Liver Studies, Kings College Hospital with a research interest in HIV/hepatitis B co-infection.

Andrew Dalton is a Lecturer in Social Sciences at the University of Sunderland, with research interests around HIV and AIDS, social inequalities, life histories, LGBT issues and the voluntary sector. Drew has over sixteen years’ experience within the third sector in a range of research, management and support roles. He is currently the Chair of Thrive North East, as well as the Chair of Live HIV Neutral, an activist network across the UK and the Republic of Ireland, with an aim of tackling HIV-related stigma.

Geoff Dusheiko is Emeritus Professor of Medicine at the Royal Free Hospital and University College London School of Medicine and Consultant Hepatologist at Kings College Hospital London. His research interests include the management and treatment of HCV and HBV and small hepatocellular carcinoma; he has a special interest in research on viral hepatitis, especially viral genotyping, applied molecular virology, the natural history of chronic viral hepatitis and antiviral therapies. An advisor for the NICE, he is an author of the WHO’s HCV guidelines and Director of the Skipton Fund. He is member of the Editorial Board of Journal of Viral Eradication, Co-editor of Alimentary Pharmacology and Therapeutics and has published more than 350 articles in international peer-reviewed journals or books.

Amanda Ely is a qualified social worker specialising in HIV. She began work in the field of children and families and HIV in 1997. Amanda practised as a social worker in London for a number of years before becoming a lecturer in social work at London Metropolitan University. She is an associate lecturer in Childhood Studies for the Open University, and having worked for CHIVA since 2008 she is now the CHIVA manager.

Sarah Fidler is a clinical academic in HIV/GUM at Imperial College London and Imperial College Hospital NHS Trust. She trained as an academic clinical researcher and completed a PhD in laboratory-based immunology in 1998. She also completed specialist training in medicine, and HIV and GUM and has been working in HIV clinical research for the past 20 years. Her main areas of research include the use of ART to prevent transmission and she is co-Principal Investigator of the HPTN071 (PopART) study. In addition, she runs studies testing the role of immediate treatment of acute HIV infection combined with strategic and novel intervention studies and leads the UK CHERUB collaboration on approaches towards a cure for HIV.

Final Programme 21



Caroline Foster is a Consultant in Adolescent HIV and Infectious Diseases at Imperial College Healthcare NHS Trust and is the clinical lead for transitional care in HIV. Current research studies include, the long-term outcomes for adults born with HIV, co-receptor tropism evolution within perinatal infection, the characterisation of the latent reservoir and the development of in vitro therapeutic vaccines in paediatric HIV. Research/education/guideline development and lecturing includes BHIVA, CHIVA, HYPNet, CHIPS, AALPHI, PENTA, UNICEF and WHO.

Graham Foster is the Professor of Hepatology at Queen Mary University of London and head of the Liver Unit at Barts Health. He has a long-standing interest in the management of patients with chronic viral hepatitis and is the national clinical lead for the Hepatitis C Operational Delivery Networks

Kate Gandhi has worked at Birmingham Heartlands Hospital as a specialist HIV pharmacist for nearly 10 years. She is an independent prescriber, a member of the Faculty of the Royal Pharmaceutical Society and a past-member of the CHIVA Executive Committee

Yvonne Gilleece is a Consultant in HIV and Sexual Health at Brighton and Sussex University Hospitals NHS Trust. She has a special interest in HIV and Women and is Steering Group Lead for SWIFT. She is the Lead for HIV in Fertility, Conception and Pregnancy and also specialises in HIV and Hepatology in Brighton. She is Chair of the upcoming BHIVA guidelines on the management of HIV infection in pregnant women and the update of the BHIVA/BASHH sexual and reproductive health guidelines. She regularly publishes clinical research and presents nationally and internationally.

Richard Gilson is a Reader in Sexual Health and HIV at University College London, Head of the Research Department of Infection and Population Health, and Director of the Centre for Sexual Health and HIV Research. Richard's particular interests include HIV and viral hepatitis co-infection (prevalence, transmission, natural history, immunology and response to treatment), and he is the principal investigator on the STOP-HCV-1 treatment strategy trial at the Mortimer Market Centre. Richard’s other interests include HIV cohort studies and HPV disease.

Tom Harrison is Professor of Infectious Diseases and Medicine and Deputy Director of the Institute for Infection and Immunity at St Georges University of London, and Consultant at St Georges Hospital, London. He trained in infectious diseases in London, and in Boston, USA. He leads a clinical research programme on the prevention and treatment of cryptococcal meningitis, developed first in Thailand, and subsequently across sites in sub-Saharan Africa.He is also involved in Phase II and III trials of chemotherapy for tuberculosis. He has served on the cryptococcal guidelines panels of IDSA, the Southern African HIV Clinicians Society and WHO.

William Irving has been Professor and Honorary Consultant in Virology at the University of Nottingham and Nottingham University Hospitals NHS Trust since 2002. His research interest is in the natural history of hepatitis C virus infection. He co-chairs HCV Research UK, a multi-centre consortium creating a national cohort, clinical database and biobank of 10,000 patients infected with HCV. He is a keen bridge player, and being Leeds born-and bred, has a passion for the fortunes of Leeds United and Leeds Rhinos.

Ali Judd is an epidemiologist at the MRC Clinical Trials Unit at UCL. She co-leads the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC), and leads the UK/Irish CHIPS, CHIPS+ and AALPHI cohorts. She also contributes to the Collaborative Initiative for Paediatric HIV Education & Research (CIPHER) Cohort collaboration.

Saye Khoo is Professor in the Institute of Translational Medicine at the University of Liverpool. He combines practise in Infectious Diseases at the Royal Liverpool University Hospital (chairing the Mersey, Cheshire & N Wales HIV Network), with leading an active research programme in infection pharmacology, focusing on HIV, and more recently tuberculosis and hepatitis C. Research is guided by clinical need, and integrates clinical pharmacokinetics with molecular pharmacology through quantitative modelling approaches. Two web-based prescribing support tools for managing drug interactions (www.hiv-druginteractions.org and www.hep-druginteractions.org) and accompanying smartphone Apps are widely utilised in clinical practice.


12–14 October 201622


Nigel Klein is a Professor and Consultant in Paediatric Infectious Diseases and Immunology at Great Ormond Street Children’s Hospital, London, the Institute of Child Health, University College London and at the African Health Research Institute in South Africa. He has worked in the field of infectious diseases for many years with particular interests in meningitis, sepsis, innate immunity, premature labour and HIV. He has been a member of several national and international boards and is a member of the PENTA Immunology and Virology committee. He has published more than 300 papers and supervised more than 30 PhD students of whom more than half have been Clinical Fellows.

Ranjababu Kulasegaram (Babu) is a Consultant in HIV/GU Medicine at St Thomas’ Hospital and leads the HIV Treatment Advice Clinic, with special interests in HIV/hepatitis, haemophilia/HIV infection, HIV/neurocognitive function and HIV inpatient management. Babu is committed to enhancing BHIVA’s educational activities through his involvement as a course director for the BHIVA General Medicine Course, his contributions as one of the leads for the Diploma in HIV Medicine Revision Course, and as a current member of the BHIVA Hepatitis Society and EHHC Programming committee. Babu is an examiner for the Diploma in HIV Medicine, immediate past Chair of the BHIVA Hepatitis Society and also served as Vice Chair of the BHIVA Education and Scientific subcommittee.

Jordan Lake is Associate Professor at the University of Texas Health Science Center McGovern School of Medicine in Houston, TX. She completed both medical school and Internal Medicine residency at Baylor College of Medicine in Houston, Texas, followed by an Infectious Diseases fellowship at the University of California, Los Angeles. Her research focuses on the treatment of metabolic and ageing-related complications of HIV and antiretroviral therapy.

Nicola Mackie is a Consultant Physician and Head of Speciality for HIV at Imperial College Healthcare NHS Trust. Her research was in the field of HIV-1 drug resistance and she runs the weekly Virtual Clinic. She is also the Clinical Lead for the HIV Women’s Service at Imperial. She is involved with writing national guidelines, examining for dipHIV and teaching for BASHH and EACS. She has recently been elected as a Trustee member of the BHIVA Executive committee.

Ula Mahadeva is a Consultant Histopathologist at Guy’s and St Thomas’ NHS Foundation Trust where her areas of subspecialisation are gastrointestinal histopathology, gynaecological and non-gynaecological cytopathology, consented and maternal death autopsies, and infectious disease histopathology. She is known within the department and region for her enthusiasm for teaching and training, including helping trainees with preparation for the FRCPath examination, and is an RCPath examiner.

Vincent Mallet has worked on basic and clinical aspects of liver diseases since 1999. His main areas of interest and contributions include burden of viral hepatitis and outcomes of treatments, viral hepatitis in immunocompromised hosts, immunopathogenesis of HCV, HBV and HEV infections, novel immunomodulatory therapies for cancer and hepatocellular carcinoma, big-data to describe the natural courses of diseases. He has published many articles in international peer-reviewed journals and is an Associate Editor for the Journal of Antimicrobial Chemotherapy, and a reviewer for several journals.

Gail Matthews is trained as an HIV/sexual health specialist in London and an Infectious diseases Physician in Australia. She currently holds a position as a clinical academic in HIV/Infectious Diseases at St Vincent’s Hospital and is an Associate Professor in the Viral Hepatitis Clinical Research Program at the Kirby Institute, UNSW. She completed her PhD on therapeutic strategies in HIV/HBV confection and has a particular interest in HIV/ viral hepatitis confection including acute hepatitis C, antiviral resistance and marginalised populations.

Claire McCausland is a Senior Lecturer at the University of Central Lancashire, where she is Course Leader for the BSc (Hons) Sexual Health Studies programme. She is an NMC-registered Nurse and has been practising in sexual health and HIV care and management since 2003; Claire's role prior to joining the University was in working in support of vulnerable sexually active under 18-year-olds.


Final Programme 23


Karim Meeran did his undergraduate and postgraduate training in London, and then proceeded to an academic career at Imperial College. He is a Fellow both of the Royal College of Physicians and the Royal College of Pathologists. He has become the Training Programme Director for Metabolic Medicine and Endocrinology in London and is on the Educational Committee for the European Society of Endocrinology. He has over 100 peer-reviewed articles and has published on Cushing’s syndrome, pituitary diseases, and the gut hormone control of food intake and appetite. He runs a successful Endocrinology and Advanced Diabetes training course and is responsible for the training of specialists in endocrinology in London.

Jackie Nicholson is a Clinical Psychologist and has been working with young people and their families with mental health issues for 13 years. Now working with the Paediatric HIV team based at North Manchester District General, she provides psychological assessment and care directly to young people with HIV, as well as supporting their families and carers. Jackie's work also involves contributing to the paediatric multidisciplinary team, working with schools, social care and voluntary agencies. She uses an integrative approach in her assessments and interventions; however, she is mostly influenced by systemic and family psychotherapy.

Nneka Nwokolo is a Consultant Physician in HIV/GUM at 56 Dean Street, Chelsea and Westminster Hospital. She has a particular interest in HIV prevention and jointly established the first PrEP clinic in the UK. She has been actively involved in the development of guidelines for the monitoring of individuals on generic PrEP and is involved in clinical studies of PrEP and of early treatment of HIV infection. She established the Dean Street cohort, a prospective study of HIV-positive patients at 56 Dean Street, a clinic that makes over 400 new HIV positive diagnoses/year of which 45% are incident infections.

Chloe Orkin is a Consultant Physician and Honorary Reader in HIV Medicine at the Royal London Hospital where her clinical duties include running a busy HIV and HIV/HCV research unit. Her specialist interests are: antiretroviral therapy, hepatitis and oncology. She is Chair Elect of the British HIV Association. She has over 90 peer-reviewed publications and has been a co-author on four BHIVA guidelines . Chloe is the External Examiner to the Diploma in HIV Medicine. She is actively researching ways of implementing HIV and blood-borne virus testing.

Jean-Michel Pawlotsky is Professor of Medicine at the Université Paris-Est. He is the Director of the National Reference Center for Viral Hepatitis B, C and Delta and of the Department of Virology at the Henri-Mondor University Hospital, Créteil, France, and Director of the Academic Department ‘Viruses, Immunity and Cancers (INSERM U955). He was acting Secretary General of EASL and an Associate Editor of both Hepatology and Gastroenterology. He has published over 500 articles and book chapters and is a regular speaker at international meetings.

Frank Post is a consultant physician in HIV Medicine and HIV Research Lead at King’s College Hospital, London. His research is focused on kidney disease in HIV infection and the effects of antiretroviral therapy on kidney and bone. He has published more than 100 papers and been a co-author on several BHIVA guidelines and the British Transplantation Society guidelines for kidney transplantation in patients with HIV.

Waseem Qasim is NIHR Professor of Cell and Gene Therapy at Great Ormond Street Institute of Child Health and Consultant in Paediatric Immunology and Bone Marrow Transplantation. His group is leading delivery T cell therapies in transplantation including lentiviral engineered T cell therapies for leukaemia. In 2015, the successful application of gene-editing technology to treat two infants with leukaemia created headline news. Similar approaches are being developed to confer resistance to HIV, including by co-receptor gene-editing and the transfer of antiviral restriction factors.

Tim Rhodes is a Professor in Public Health Sociology at the London School of Hygiene and Tropical Medicine, and Conjoint Professor of the Sociology of Health at the University of New South Wales. He uses qualitative methods to explore narratives of self and health, including in relation to risk environments mediating HIV, hepatitis C and injecting drug use. His current research focuses on the social relations of access to HIV prevention, treatment and care, including among people who inject drugs in East Africa and among people living with HIV and hepatitis C in the UK.



12–14 October 201624


Alison Rodger is a Reader in Infectious Diseases at University College London, and Consultant in Infectious Diseases/HIV and Director of Public Health at the Royal Free Hospital in London. Alison is a co-author of BHIVA guidelines on hepatitis co-infection, immunisations and post-exposure prophylaxis. She co-chairs the guideline writing group for PrEP. Her academic interests are HIV transmission, testing and prevention.

Marie Rousseau is a Specialist Practitioner in HIV Welfare and Support based at Kings College Hospital. She works in both in- and out-patient settings, providing welfare and support to individuals, particularly those with complex needs. She manages integrated care pathways, overseeing service use across community health, social care and voluntary sectors, focusing on engagement in care. She facilitates the multidisciplinary team meetings, working very closely alongside the HIV community team, HIV mental team and the patient representative. She has considerable experience of working with marginalised groups of people, in particular those who have experienced stigma, prejudice and discrimination, enabling them to address health inequalities through community engagement and empowerment. Her main interests are around HIV service delivery and end-of-life care and she volunteers at St Christopher’s Hospice.

Caroline Sabin is Professor of Medical Statistics and Epidemiology at University College London (UCL) and is Director of the National Institutes for Health Research (NIHR) Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections, a partnership between UCL, Public Health England (PHE) and the London School of Hygiene and Tropical Medicine. Caroline has worked for many years on the analysis of large observational HIV databases with a particular interest in raising awareness of the biases inherent in these databases; she is the principal investigator on the UK CHIC Study, the principal statistician on the D:A:D Study, co-principal investigator on the POPPY Study, and has worked with many other research groups in the UK and elsewhere.

Liat Sarner has been a consultant in Sexual Health and HIV at The Royal London Hospital since 2003 and is Clinical Director of Sexual Health and HIV services across Barts Health NHS Trust. She has a particular interest in HIV and women including conception, pregnancy and menopause, runs the antenatal HIV service and is part of the London HIV pregnancy research group.

Maryam Shahmanesh is a Senior Lecturer in the Centre for Sexual Health and HIV research and an Honorary Consultant in Sexual Health and HIV Medicine at the Mortimer Market Centre. After graduating in Medicine, Maryam completed her specialist training in Sexual health and HIV medicine. Her academic training, which has complemented her clinical training, includes a degree in Social and Political Science, a Masters in Epidemiology, and a PhD in Clinical Epidemiology.

Ruth Simmons is an epidemiologist with PHE within the Health Protection Research Unit, leading on mapping the cascade of care for blood-borne viruses (BBV) through data linkage. Ruth is also the lead for the sentinel surveillance of BBV testing. Ruth has a Masters in Epidemiology, and has recently completed a PhD estimating HIV incidence in Ukraine, Poland and Estonia. Ruth was also a member of the WHO working group on HIV incidence assays, developing technical guidelines for determining HIV incidence using case-based surveillance data and recent infection testing algorithms.

John Soong is an RCP Clinical Quality Improvement Research and Training Fellow. He is undertaking Doctoral Research with Imperial College London studying risk stratification for Frailty in the Acute Medical Care setting. John is a clinical doctor with joint accreditation in the subspecialties of Acute Medicine and Intensive Care Medicine. He is a member of the Patient Safety Committee at the Royal College of Physicians and was a member of the data workstream for the Future Hospital Commission. He has been involved in a number of national quality improvement initiatives including HQIP Audit of Audits, FRAILsafe and Atrial Fibrillation on the Acute Medical Unit.

Steve Taylor is the Lead HIV Consultant at Birmingham’s Heartlands Hospital and Honorary Senior Lecturer at the University of Birmingham. He has been an elected member of the BHIVA Executive committee and been a member of scientific committee for many international conferences. He sits on the Medical Advisory boards for HIV i-Base and AIDs Treatment Update, and teaches and lectures regularly to HIV-positive patient groups, as well as delivering four national courses on HIV drug resistance and pharmacology. He is Medical Director of the national HIV testing awareness charity, Saving Lives, as well as being Tri Service Consultant Advisor to HM Armed Forces and chairing the clinicians’ group for the Department of Health development of the HIV outpatient tariff. He is West Midlands Media representative for BASHH and regularly appears on television and radio to comment on issues pertaining to sexual health and HIV.


Final Programme 25


Bryan Teixeira has over 25 years’ experience leading on community-based sexual health and HIV programmes. He was the CEO of NAZ (London) for 11 years and UK National Focal Point for AIDS and Mobility Europe for 10 years. He also served for 3 years on the NGO Delegation at the UNAIDS Programme Coordinating Board as the main Delegate for Europe. Currently, Bryan works as a freelance consultant based in Carcassonne, France, and is the Chair of the Policy Working Group of the European AIDS Treatment Group (EATG), Brussels.

Melinda Tenant-Flowers is a retired Consultant in HIV/Sexual Health at King’s College Hospital, London. Her research interests included HIV oncology, HIV testing and educational assessment. She has contributed to three BHIVA guidelines. She has an MSc in Medical Education, is lead for BHIVA e-Learning CPD and a member of the BHIVA Education/Scientific, Conferences and Website Subcommittees. She has been an examiner for the Diploma in HIV Medicine since its foundation, was Convenor of the Diploma in Genitourinary Medicine, STC co-chair and ARCP representative (London) and contributed to the latest HIV curriculum revision for the SAC and RCP.

Emma Thomson is an Infectious Diseases Physician and Clinical Senior Lecturer in Virology in Glasgow. She runs a co-infection treatment clinic in Glasgow and runs a laboratory funded by the Wellcome Trust and the MRC that carries out research into HCV immunity using next-generation sequencing and functional B and T cell assays. She is a member of the WHO HCV treatment guidelines committee.

Alicia Thornton has worked in HIV surveillance and research since 2005. Her previous research interests have included HIV testing and sexual behaviour. In 2011 Alicia joined University College London to work on the UK CHIC study with a particular focus on hepatitis co-infection.

Mark Thursz is Professor of Hepatology at Imperial College where he is head of the Digestive Diseases Division and also Lead Cinician for Hepatology at St Mary's Hospital, London. His clinical interests are in viral hepatitis, alcoholic and fatty liver disease.

Emmanuel Tsochatzis is a Senior Clinical Lecturer and Consultant Hepatologist at the University College London Institute for Liver and Digestive Health, Royal Free Hospital, London. He was the recipient of the Rising Star in Gastroenterology prize by the UEG and the EASL Physician Scientist Fellowship in 2014. His research interests include non-alcoholic fatty liver disease, cirrhosis and portal hypertension, and non-invasive assessment of liver fibrosis. His work on the cost-effectiveness of non-invasive fibrosis tests has informed the WHO guidelines on diagnosis and treatment of both HBV and HCV. He has published more than 120 articles in peer-reviewed journals.

Andrew Ustianowski is a Consultant and Research Lead at the Regional Infectious Diseases Unit, Manchester, and Chair of the British Viral Hepatitis Group. He is a co-author of co-infection and other national guidance, and lectures widely on HIV, hepatitis and associated subjects.

Yvonne Vaughan-Gordon is the Lead Nurse for the West Midlands Region, the largest Paediatric HIV centre for children outside London. She has been involved in caring for children and their families since 2000, when the first children presented with life-threatening symptoms such as PCP. Children were hospitalised for months on end and treatment regimens were difficult to maintain due to restrictions and undesirable side effects. The survival of these newly diagnosed positive children was very uncertain. However, 16 years later their futures look bright. They are now looking forward and thinking about their own future careers and families. The road at times has been rocky and uncertain but Yvonne is proud to say that she has walked with them, been witness to their courage and tenacity, and looks forward to seeing how much more they can achieve in the future.

Peter Vickerman is a Professor in Infectious Disease Modelling at the University of Bristol. His research focuses on the use of mathematical modelling to help understand the transmission of different infectious diseases and the impact and cost-effectiveness of prevention measures. Specific expertise focuses on the transmission of HIV, HCV and other STIs amongst different high-risk groups including injecting drug users. He has extensive experience of conducting collaborative research with organisations in Asia, sub-Saharan Africa, Eastern Europe and the UK.



12–14 October 201626


Charlotte Warren-Gash is an academic public health doctor. Her main research interest is using linked electronic health records and biological data to investigate the effect of infections on the course of chronic diseases to inform personalised prevention. She has recently been awarded a Wellcome Trust intermediate clinical fellowship at the London School of Hygiene and Tropical Medicine. She also contributes to policy work as a visiting fellow at the Foundation for Genomics and Population Health in Cambridge.

Laura Waters is a Consultant at the Mortimer Market Centre in London where she is HIV and Hepatitis Service Lead. She was Vice-Chair of the 2015 BHIVA guidelines on the treatment of HIV-1-positive adults with antiretroviral therapy and now chairs this group; she is Vice-Chair of the BHIVA Conferences subcommittee and Chair of the BASHH HIV Special Interest Group. Laura has an MD in antiretroviral simplification and switch, and is Principal Investigator for several first-line and switch studies at Mortimer Market.

Ed Wilkins is an Infectious Diseases Physician at North Manchester General Hospital in the UK, and holds Honorary positions at Manchester and Liverpool Universities. Dr Wilkins trained in infectious diseases in the UK, tropical medicine in Africa, and clinical microbiology and virology with the UK Health Protection Agency. He has been involved with HIV patient care and research since 1982, with particular interests in antiretroviral toxicity, hepatitis and TB co-infection, HIV and the brain, and treatment as prevention. Dr Wilkins is involved in many national executive and advisory committees, including the British HIV Association (BHIVA). He is a co-author on several National Guidelines and is chair of the BHIVA hepatitis co-infection guideline writing committee.

Amanda Williams has been a Consultant Paediatrician and Specialist in Paediatric Infectious Diseases at London North West Healthcare NHS Trust since 2002. She is lead for Paediatric HIV and Tuberculosis. Amanda has previously been Honorary Secretary of CHIVA and Chair of the CHIVA guideline group. She is a co-author of the CHIVA Standards of Care for Infants, Children, and Young People with HIV. She is the current Chair of the Children's HIV Association.


Final Programme 27


FORTHCOMING EVENTS AND MAJOR SPONSORS 2016

FORTHCOMING EVENTS

23rd Annual Conference of the British HIV Association (BHIVA)

4–7 April 2017 Arena and Convention Centre, Liverpool

BHIVA General Medicine for HIV Physicians Course

Thursday 3 November 2016 NCVO, London

BHIVA/BVHG Hepatology Highlights

Thursday 24 November 2016 Radisson Blu Hotel, Birmingham

BHIVA World AIDS Day

'How to Survive a Plague'Wednesday 30 November 2016

Curzon Soho, London

BHIVA/BASHH Course on Mentoring Skills for Sexual Health/HIV Physician

Friday 9 December 2016 Medical Research Council Head Office, London

BHIVA 'Best of CROI' Feedback 2017

Monday 27 February 2017, LondonTuesday 28 February 2017, EdinburghWednesday 1 March 2017, WakefieldThursday 2 March 2017, CardiffTuesday 7 March 2017, BirminghamWednesday 8 March 2017, HaydockThursday 9 March 2017, Newcastle

BHIVA MAJOR SPONSORS 2016

Bristol-Myers Squibb Pharmaceuticals Ltd

Uxbridge Business Park Sanderson Road Middlesex UB8 1DH

Gilead Sciences Ltd

280 High Holborn London WC1V 7EE

Janssen

50–100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4DP

ViiV Healthcare UK Ltd

Stockley Park West Uxbridge Middlesex UB11 1BT

MSD Ltd

Hertford Road Hoddesdon Hertfordshire EN11 9BU

BHIVA major sponsors and commercial exhibitors havesupported the BHIVA Autumn Conference by purchasingexhibition stand space.

Conference Organiser: Mediscript Ltd,1 Mountview Court,

310 Friern Barnet Lane, London N20 0LDT: +44 (0) 20 8369 5380 F: +44 (0)20 8446 9194

E: [email protected]

+ +

TRIUMEQ and TIVICAY are registered trademarks of the ViiV Healthcare group of companies.©2016 ViiV Healthcare group of companies All rights reserved. Date of preparation: September 2016 VIIV/DGR/0079/16

For your treatment-naïve patients and for patients who may benefit from a change in ART regimen, CHOOSE...

SUPERIOR EFFICACY

in treatment-naïve patients vs Atripla®, darunavir/r

and atazanavir/r (in women)1-3

HIGH BARRIER TO RESISTANCE

0 resistance to dolutegravir-based regimens in treatment-naïve trials1-5

BOOSTER-FREE DOSING

with few clinically significant drug-drug interactions5

dolutegravir/abacavir/lamivudinedolutegravir/abacavir/

lamivudine

DOLUTEGRAVIRAT THE CORE

BUILD A REGIMEN WITH

THE ONLY INI THAT OFFERS ALL OF THE FOLLOWING:

TRIUMEQ is indicated for the treatment of HIV-infected adults and adolescents above 12 years of age weighing at least 40 kg.Before initiating treatment with abacavir-containing products, HLA-B*5701 status must always be documented. Abacavir should not be used in patients known to carry the HLA-B*5701 allele due to the risk of hypersensitivity reaction.TIVICAY is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adults and adolescents above 12 years of age.

Tivicay® dolutegravir 50mg tabletsSee Summary of Product Characteristics before prescribingIndication: HIV in >12 years and ≥40kg as part of combination therapy. Dosing: 50mg once daily with or without food if no proven/ suspected integrase resistance. 50mg twice daily with efavirenz, nevirapine, tipranavir/ritonavir, etravirine (without boosted PI), carbamazepine, oxcarbazepine, phenytoin, phenobarbital, St John’s Wort or rifampicin. Adults with proven/ suspected integrase resistance: 50mg twice daily preferably with food. Elderly: Limited data in 65+ yrs. Caution in severe hepatic impairment. Contraindications: Hypersensitivity to any ingredient. Co-administration with dofetilide. Warnings/precautions: Risk of hypersensitivity reactions. Discontinue dolutegravir and other suspect agents immediately if suspected. Risks of osteonecrosis, immune reactivation syndrome. Monitor LFTs in Hepatitis B/C co-infection and ensure effective Hepatitis B therapy. Caution with metformin: monitor renal function and consider metformin dose adjustment. Use with etravirine requires boosted PI or increased dose of dolutegravir. Use with Mg/Al-containing antacids, calcium, multivitamins or iron requires dosage separation. Pregnancy/ lactation: Not recommended. Avoid breast-feeding. Side effects: See SPC for full details. Headache, GI disturbance, insomnia, abnormal dreams, depression, dizziness, rash, pruritus, fatigue, elevations of ALT, AST and CPK, hypersensitivity, suicidal ideation or suicide attempt. Basic NHS costs: 30 tablets £498.75 EU/1/13/892/001. MA holder: ViiV Healthcare UK Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS. Further information available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT. POM

Tivicay is a registered trademark of the ViiV Healthcare Group of Companies Date of approval: August 2015 Zinc code: UK/DLG/0055/13(7)

Adverse events should be reported. For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

Adverse events should be reported. For Ireland, adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971, [email protected]. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

References: 1. Walmsley S et al. J Acquir Immune Defic Syndr. 2015;70(5):515-519. 2. Molina J-M et al. Lancet HIV. 2015;2(4):e127-e136. 3. Orrell C et al. Presented at: Annual International AIDS Conference; July 18-22, 2016; Durban, South Africa. Abstract THAB0205LB. 4. Raffi F et al. Lancet Infect Dis. 2013;13(11):927-935. 5. TIVICAY (dolutegravir) Summary of Product Characteristics. September 2015.

Prescribing Information Triumeq® dolutegravir 50mg/abacavir 600mg/lamivudine 300mg tablets See Summary of Product Characteristics before prescribing. Indication: HIV in over 12 years and ≥ 40kg. Screen for HLA-B*5701 prior to use. Do not use if HLA-B*5701 positive. Dose: one tablet once daily with or without food. Elderly: Limited data in 65+ yrs. Creatinine clearance <50ml/min or moderate/severe hepatic impairment: Not recommended. Contraindications: Hypersensitivity to any ingredient. Co-administration with dofetilide. Warnings/precautions: Both abacavir and dolutegravir are associated with risk of hypersensitivity reactions (HSR). Do not initiate in HLA-B*5701+ or previous suspected abacavir HSR. Stop Triumeq without delay if HSR suspected. Never reintroduce any dolutegravir- or abacavir-containing product after suspected HSR. Risks of immune reactivation syndrome, osteonecrosis, increased weight, lipids, glucose. Monitor LFTs in Hepatitis B/C co-infection. Inconclusive data on relationship between abacavir and MI; minimise all modifiable CV risk factors (e.g. smoking, hypertension, hyperlipidaemia). Not recommended if dolutegravir required b.d. (with etravirine [without boosted PI], efavirenz, nevirapine, rifampicin, boosted tipranavir, carbamazepine, oxcarbazepine, phenytoin, phenobarbital and St John’s Wort). Use with cladribine not recommended. Use with Mg/Al-containing antacids, calcium, multivitamins or iron requires dosage separation. Caution with metformin: monitor renal function and consider metformin dose adjustment. Pregnancy/lactation: Not recommended. Avoid breast-feeding. Side effects: See SPC for details. Headache, insomnia, sleep/dream disorders, GI disturbance, fatigue, hypersensitivity, anorexia, depression, dizziness, somnolence, lethargy, malaise, cough, nasal symptoms, rash, pruritus, alopecia, arthralgia, muscle disorders, asthenia, fever, elevations of ALT, AST and CPK, blood dyscrasias, suicidal ideation or suicide attempt, rhabdomyolysis, lactic acidosis, erythema multiforme, Stevens- Johnson syndrome, toxic epidermal necrolysis. Basic NHS costs: 30 tablets: £798.16 EU/1/14/940/001. MA holder: ViiV Healthcare UK Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS. Further information is available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT. POM

Triumeq is a registered trademark of the ViiV Healthcare Group of CompaniesDate of approval: July 2016 Zinc code: UK/TRIM/0037/14(5)

SPECSLIVE: (186mm X 260mm)TRIM: (210mm X 297mm)BLEED: (224mm X 311mm)

S:186 mmS:260 m

mT:210 mm

T:297 mm

B:224 mmB:311 m

m

bhiva autumn conference

Documents